The U.S. Department of Health and Human Services (HHS) has announced the termination of 22 contracts, canceling nearly $500 million in funding for mRNA vaccine development at the Biomedical Advanced Research and Development Authority (BARDA). The decision follows claims that mRNA vaccines do not protect effectively against respiratory infections like COVID-19 and influenza. This move represents a significant shift away from a technology that underpinned the swift development of COVID-19 vaccines under the previous administration. The termination has sparked criticism from experts who emphasize mRNA's speed and programmability, considering it essential for pandemic preparedness and broader medical applications including cancer immunotherapy. Industry and scientific communities warn that this pivot endangers U.S. readiness for future pandemics and bioterror threats. The controversy is compounded by political dynamics and has caused concern among companies developing mRNA-based therapies.